Clinical trials: Proteinuric Kidney Diseases
Minimal Change Disease (MCD), IgA Nephropathy (IgAN)
Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases
This is a Phase 1b/2, open-label, multi-center study evaluating the therapeutic potential and safety of the investigational drug EVER001 in adults with FSGS, MCD, or IgAN.
- Conditions
- Minimal Change Disease (MCD), IgA Nephropathy (IgAN), Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- NCT07614477
- Testing
- EVER001
- Where
- 2 sites in China
- Volunteers
- 45 people
- Sponsor
- Everest Medicines (China) Co.,Ltd.
Chronic Kidney Disease, Proteinuria
Endothelin Receptor Antagonism in Proteinuric Nephropathy
The number of people with kidney problems is increasing rapidly, related in part to the increasing prevalence of diabetes. Patients with kidney problems tend to have protein leaking into the urine (proteinuria).
- Trial name
- NCT00722215
- Testing
- BQ-123 (selective endothelin A receptor antagonist), 0.9 % saline, Nifedipine
- Where
- United Kingdom
- Volunteers
- 22 people
- Sponsor
- University of Edinburgh
Proteinuric Kidney Diseases
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
This study is open to adults with certain kidney conditions, including secondary focal segmental glomerulosclerosis (sFSGS), treatment-resistant primary minimal change disease (TR-pMCD), Alport Syndrome (AS), and…
- Trial name
- NCT07355296
- Testing
- BI 764198
- Where
- 154 sites in United States, Argentina and 30 more
- Volunteers
- 132 people
- Sponsor
- Boehringer Ingelheim
Chronic Kidney Disease
A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease
The purpose of the study is to evaluate the dose-response efficacy, safety, and pharmacokinetics (PK) of AZD5718 in participants with proteinuric chronic kidney disease.
- Trial name
- NCT04492722
- Testing
- AZD5718, Dapagliflozin 10 mg
- Where
- 111 sites in United States, Argentina and 9 more
- Volunteers
- 613 people
- Sponsor
- AstraZeneca
Proteinuria
Effect of Oral Supplementation With Curcumin (Turmeric) in Patients With Proteinuric Chronic Kidney Disease
The purpose of this study is to determine if the oral supplementation with curcumin reduces proteinuria in patients with chronic kidney disease regardless the ethiology.
- Trial name
- NCT01831193
- Testing
- Curcumin
- Where
- Mexico
- Volunteers
- 120 people
- Sponsor
- Instituto Nacional de Cardiologia Ignacio Chavez
Proteinuric Kidney Disease
A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease
The purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease.
- Trial name
- NCT06830629
- Testing
- MZE829
- Where
- 79 sites in United States, France and 1 more
- Volunteers
- 74 people
- Sponsor
- Maze Therapeutics
Hypertension (HTN)
A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease
A study Comparing the Clinical Benefit of Finerenone Versus a Fixed-Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients with Hypertension and Chronic Kidney Disease.
- Trial name
- NEPHRON (NCT07223502)
- Testing
- Combination Product: FDC of spironolactone and ER torsemide, Combination Product: Stabilized doses of loop diuretic and finerenone
- Where
- United States
- Sponsor
- Sarfez Pharmaceuticals, Inc.
Uric Acid Nephropathy
Losartan and Uric Acid Metabolism in Children With Proteinuric Nephropathies
The aim of this study is to assess the serum uric-acid lowering effect of losartan in children with proteinuric nephropathies. Patients already treated with enalapril will be randomized to receive losartan and/or enalapril in a…
- Trial name
- NCT05402397
- Testing
- Losartan Potassium
- Where
- Argentina
- Volunteers
- 40 people
- Sponsor
- Hospital General de Niños Pedro de Elizalde
IGA Glomerulonephritis
Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis
This study evaluates prospectively the effects of an anti-angiotensin II regimen on renal outcome in patients with mesangioproliferative glomerulonephritis followed-up for 10 years.
- Trial name
- NCT01115426
- Testing
- Ramipril or losartan
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- University Magna Graecia
Primary Membranous Nephropathy
Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001
EVER001 is a highly selective, oral, reversable, covalent Bruton tyrosine kinase (BTK) inhibitor with high selectivity over other kinases, which is being developed to treat proteinuric glomerular diseases.
- Trial name
- NCT05800873
- Testing
- EVER001
- Where
- 19 sites in China
- Volunteers
- 31 people
- Sponsor
- Everest Medicines (China) Co.,Ltd.
Proteinuria, Chronic Kidney Diseases
Efficacy and Safety of Dapagliflozin in Children With Proteinuric Chronic Kidney Disease
We aim to investigate the antiproteinuric effect of adding Dapagliflozin to the standard of care in children with proteinuria.
- Trial name
- NCT04531397
- Testing
- ACEI treatment, Dapagliflozin+ACEI treatment
- Where
- China
- Sponsor
- Children's Hospital of Fudan University
Diabetic Nephropathy
Minocycline and Proteinuria in Diabetic Nephropathy
Diabetic kidney disease increases the risk of illness and death from heart disease in patients with Type 2 diabetes. Some blood pressure medications called ACE inhibitors and ARBs slow progression of kidney disease, but the dose…
- Trial name
- NCT01779089
- Testing
- Minocycline 100 mg po bid for 6 months
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Fabry Disease, Proteinuria
The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study
The primary hypothesis is that titration of ACE inhibitor and Angiotensin Receptor Blockers (ARBs)to reduce urine protein excretion to < 500 mg per day in Fabry Patients receiving agalsidase beta therapy at 1 mg/kg every two…
- Trial name
- FAACET (NCT00446862)
- Testing
- enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers
- Where
- 6 sites in United States, Slovenia
- Volunteers
- 36 people
- Sponsor
- University of Alabama at Birmingham
Renal Disorder
Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213)
Antiproteinuric Efficacy of Losartan Potassium in Patients with Non-Diabetic Proteinuric Renal Diseases.
- Trial name
- NCT00140985
- Testing
- MK0954, losartan potassium/Duration of Treatment: 20 weeks, Comparator: amlodipine / Duration of Treatment: 20 weeks
- Volunteers
- 97 people
- Sponsor
- Organon and Co
Proteinuric Renal Disease, Proteinuric Kidney Disease
Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria
Single-center, open-label, two-stage pilot study examining the efficacy and safety of sparsentan for reducing high-grade proteinuria among patients with cancer who receive vascular endothelial growth factor inhibitors
- Conditions
- Proteinuric Renal Disease, Proteinuric Kidney Disease, Proteinuria, Proteinuria in Nephrotic Range
- Trial name
- NCT07224776
- Testing
- sparsentan, No sparsentan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Brigham and Women's Hospital
Microalbuminuria, Macroalbuminuric Diabetic Nephropathy
Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients
Study Hypothesis: Reduction in albuminuria has been shown to decrease progression of diabetic nephropathy. In diabetic nephropathy patients treated with maximal antihypertensive doses with dual RAAS blockade (total daily dose…
- Conditions
- Microalbuminuria, Macroalbuminuric Diabetic Nephropathy, Diabetes, Proteinuria
- Trial name
- NCT00961207
- Testing
- Aliskiren
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Cook County Health
Kidney Disease
Aliskiren Combined With Losartan in Proteinuric, Non-diabetic Chronic Kidney Disease
Study objective: To investigate the potential anti-proteinuric and renoprotective efficacy of aliskiren in addition to losartan in patients at risk of developing end-stage renal disease (ESRD) Methods: This will be a randomized…
- Trial name
- NCT01150201
- Testing
- Aliskiren, Losartan
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The University of Hong Kong
Heavy Proteinuria
Anti-Proteinuric Response to ACEI, ARB and Diuretics Combination.
Determine the best strategy for proteinuria lowering in patients with proteinuria > 1 g/day receiving ACEI and ARB combination: either increase of ACEI and ARB dosage or increase of diuretic dosage.
- Trial name
- NCT00200694
- Testing
- ramipril 5 mg + valsartan 80 mg/day,, ramipril 10 mg + valsartan 160 mg/day,, ramipril 5 mg + valsartan 80 mg/day + increased dosage of furosémide.
- Where
- France
- Volunteers
- 18 people
- Sponsor
- Nantes University Hospital
Renal Insufficiency, Chronic, Proteinuria
Effect of RAS Blockers on CKD Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)
This study evaluates the effect of renin-angiotensin blockers on chronic kidney disease progression in elderly (>65 years old) patients with non-proteinuric nephropathies.
- Trial name
- PROERCAN01 (NCT03195023)
- Testing
- Lisinopril, Amlodipine
- Where
- Spain
- Volunteers
- 106 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
Chronic Kidney Disease
Sevelamer in Proteinuric CKD
Progressive renal impairment in chronic kidney diseases (CKD) may cause inability to excrete phosphate load, thus leading to the typical abnormalities of the mineral metabolism, such as increased phosphate and reduced calcium…
- Trial name
- ANSWER (NCT01968759)
- Testing
- Sevelamer, Ramipril and Irbesartan
- Where
- 2 sites in Italy
- Volunteers
- 53 people
- Sponsor
- Mario Negri Institute for Pharmacological Research